Frederic Viret
Overview
Explore the profile of Frederic Viret including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1048
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giraudo A, Sabatier R, Rousseau F, de Nonneville A, Goncalves A, Cecile M, et al.
Cancers (Basel)
. 2024 May;
16(10).
PMID: 38791919
Background: Breast cancer (BC) incidence increases with age, particularly in HR-positive/HER2-negative subtypes. Cyclin-dependent kinase 4 and 6 inhibitors (CDK 4/6is) alongside endocrine therapy (ET) have emerged as promising treatments for...
2.
Houvenaeghel G, de Nonneville A, Cohen M, Sabiani L, Buttarelli M, Charaffe E, et al.
Cancer Med
. 2024 Feb;
13(3):e6930.
PMID: 38327130
Aim: We investigated the pathologic complete response rates (pCR) and survival outcomes of early breast cancer patients who underwent neoadjuvant chemotherapy (NAC) over 14 years at a French comprehensive cancer...
3.
Mosele F, Deluche E, Lusque A, Le Bescond L, Filleron T, Pradat Y, et al.
Nat Med
. 2023 Jul;
29(8):2110-2120.
PMID: 37488289
The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-HER2-drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial evaluated the efficacy of T-DXd...
4.
Mugnier B, Goncalves A, Daumas A, Couderc A, Mezni E, Viret F, et al.
Osteoporos Int
. 2023 Jan;
34(4):703-711.
PMID: 36715715
Purpose: This study aimed to describe changes in femoral and lumbar bone mineral density (BMD) after 24 months of aromatase inhibitors (AIs) and antiresorptive treatment in postmenopausal women with estrogen...
5.
Houvenaeghel G, de Nonneville A, Cohen M, Viret F, Rua S, Sabiani L, et al.
J Surg Res (Houst)
. 2023 Jan;
5(3):511-525.
PMID: 36714356
We examined characteristics trends in early breast cancer patients receiving neoadjuvant chemotherapy (NAC) over a 16-year period. Our primary objective was to analyze variations in tumor stage and subtype over...
6.
de Nonneville A, Houvenaeghel G, Cohen M, Sabiani L, Bannier M, Viret F, et al.
Eur J Cancer
. 2022 Oct;
176:181-188.
PMID: 36257173
Background: Half of HER2-negative breast cancers (BC) show HER2-low expression. The strong efficacy of recent anti-HER2 antibody-drug conjugates (ADC) in HER2-low tumours has risen the interest of HER2-low as a...
7.
Sabatier R, Martin J, Vicier C, Guerin M, Monneur A, Provansal M, et al.
J Clin Med
. 2021 Apr;
10(6).
PMID: 33803894
Patients And Methods: We performed a retrospective observational study to assess eribulin efficacy in patients with ABC who displayed BM at time of eribulin initiation. We collected data from the...
8.
Launay S, Sabatier R, Brunelle S, Esterni B, Tarpin C, Viret F, et al.
Anticancer Res
. 2016 Jan;
36(1):293-9.
PMID: 26722056
Background: The present monocentric and prospective phase 1 study evaluated the safety of a metronomic chemotherapy in refractory tumors. Patients And Methods: Patients with advanced solid cancer refractory to standard...
9.
Tournigand C, Chibaudel B, Samson B, Scheithauer W, Vernerey D, Mesange P, et al.
Lancet Oncol
. 2015 Oct;
16(15):1493-1505.
PMID: 26474518
Background: The combination of an anti-VEGF or an anti-EGFR-targeted monoclonal antibody with chemotherapy has shown clinical activity in patients with metastatic colorectal cancer. However, combining both anti-VEGF and anti-EGFR antibodies...
10.
Thaler J, Greil R, Gaenzer J, Eisterer W, Tschmelitsch J, Samonigg H, et al.
Ann Oncol
. 2015 Mar;
26(4):822-825.
PMID: 25814651
No abstract available.